Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233025 · ClinicalTrials.gov registry record · Phase 3
Duloxetine Versus Placebo in the Treatment of FMS
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT00233025: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00233025 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 320 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233025, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.
Interventions
- DRUG Placebo
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
What the finished NCT00233025 record still lists
NCT00233025 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00233025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00233025 about?
NCT00233025 is a clinical study titled "Duloxetine Versus Placebo in the Treatment of FMS". To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.
What is the current status of trial NCT00233025?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2005-09. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00233025?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00233025?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00233025's enrollment target sits among peer trials
320 1082nd of 2000 higher than 914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia